Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Agomelatine - Servier

Drug Profile

Agomelatine - Servier

Alternative Names: AGO-178; AGO178C; Alodil; Melitor; S-20098; S-20098-F55; Thymanax; Valdoxan; Vestin

Latest Information Update: 01 Dec 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Servier
  • Developer Novartis; Servier
  • Class Acetamides; Antidepressants; Hypnosedatives; Sleep disorder therapies; Small molecules
  • Mechanism of Action Melatonin MT1 receptor agonists; Melatonin MT2 receptor agonists; Serotonin 2C receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Major depressive disorder
  • Suspended Generalised anxiety disorder
  • No development reported Obsessive-compulsive disorders
  • Discontinued Sleep disorders

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 11 Aug 2017 Suspended - Phase-II for Generalised anxiety disorder (In adolescents, In children) in Poland, Romania, Estonia, Hungary, Sweden, Finland (PO,Tablet) (Servier email communication, August 2017)
  • 11 Aug 2017 Suspended - Phase-II for Generalised anxiety disorder in South Africa (PO, capsule) (Servier email communication, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top